Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) provides access to the company’s official U.S. regulatory disclosures as a commercial-stage biopharmaceutical and medical dermatology issuer. These documents, filed with the Securities and Exchange Commission, give detailed insight into Arcutis’ financial performance, governance, and progress in developing and commercializing therapies for immune-mediated dermatological diseases and conditions.
Key filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe product revenue from the ZORYVE (roflumilast) franchise, research and development expenses related to atopic dermatitis, plaque psoriasis, seborrheic dermatitis, and pipeline programs, as well as selling, general, and administrative costs tied to commercialization. These reports also summarize risk factors, intellectual property, and other information relevant to Arcutis’ pharmaceutical preparation manufacturing activities.
Current reports on Form 8-K document material events such as quarterly and year-to-date financial results, strategic updates, and changes in the composition of the board of directors. For example, recent 8-K filings describe the release of financial results for specific quarters and the retirement and appointment of directors, including details of compensation arrangements and consulting agreements. Such filings help investors track governance developments and corporate actions in real time.
Investors interested in executive and director compensation, equity awards, and governance policies can review proxy statements and related exhibits, while those monitoring capital structure and financing activities can examine notes in periodic reports and any registration statements or prospectus supplements that may be filed. Filings also confirm that Arcutis’ common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ARQT.
On this page, Stock Titan pairs Arcutis’ raw SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as revenue trends for ZORYVE products, major R&D milestones, and notable risk factor updates. Users can quickly scan AI-generated overviews of Forms 10-K and 10-Q, then drill into the full text for deeper analysis. Real-time ingestion from EDGAR ensures that new 8-Ks, periodic reports, and exhibits appear promptly, while structured views of ownership and transaction data make it easier to follow equity awards and other reportable items disclosed in Arcutis’ filings.
Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported insider sales executed under a 10b5-1 plan adopted on June 3, 2025 with a plan end date of September 30, 2026. The Form 4 discloses three sale transactions on October 1-2, 2025: 15,000 shares at a weighted average price of $18.9135, 9,261 shares at $20.0164, and 20,739 shares at $20.0383, totaling 45,000 shares sold. Following the last reported sale the Form shows 846,440 shares held directly by the reporting person. The filing notes multiple indirect holdings held in trusts and an LLC and includes undertakings to provide detailed per-trade price information on request.
Arcutis Biotherapeutics (ARQT): Director Howard G. Welgus reported Form 4 transactions on 10/01/2025. He exercised 9,538 stock options at $1.6806 per share and sold 9,538 shares at a weighted average price of $18.9227, plus an additional 462 shares at $18.9227. Following these trades, he directly owned 99,744 shares.
The transactions were effected under a Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026. The reported option was fully vested and carries an expiration date of 03/13/2029.
Arcutis Biotherapeutics (ARQT) filed a Form 144 reporting a proposed sale of 20,739 common shares through Merrill Lynch with an aggregate market value of $415,574, planned for 10/02/2025. The shares were acquired on 03/01/2025 via restricted stock vesting. The filing lists 119,905,078 shares outstanding for the company, which provides context for the relative size of the sale. The filer, identified in past-sales records as Todd Franklin Watanabe, sold a total of 45,937 shares in the prior three months for gross proceeds of $812,132 across four transactions dated 08/04/2025, 09/08/2025, 09/09/2025, and 10/01/2025. The filer certifies they are not aware of undisclosed material adverse information.
Arcutis Biotherapeutics (ARQT) insider filing reports a proposed sale of 24,261 common shares through Merrill Lynch on NASDAQ with an aggregate market value of $469,074 and an approximate sale date of 10/01/2025. The shares reflect restricted stock vesting events on 03/01/2025 (6,255 shares), 05/01/2025 (3,988 shares) and 08/01/2025 (14,018 shares). The filer also reported three recent sales within the past three months: 504 shares on 09/09/2025 for $8,829, 9,625 shares on 09/08/2025 for $168,800, and 11,547 shares on 08/04/2025 for $165,429.
Form 144 filing for Arcutis Biotherapeutics (ARQT) shows a proposed sale of 10,000 common shares planned for 10/01/2025 through Merrill, with an aggregate market value of $189,227. The issuer has 119,905,078 shares outstanding. The seller's holdings were acquired mostly through stock option exercise and restricted stock vesting between 2018 and 2023, totaling several thousand shares per grant. The filing also discloses two recent sales by the same person: 10,000 shares sold on 09/02/2025 for $156,383 and 10,000 on 08/01/2025 for $142,982. The signer certifies no undisclosed material adverse information.
Todd Franklin Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported planned sales of company common stock under a 10b5-1 trading plan. On 09/08/2025 he sold 9,625 shares at a weighted average price of $17.5376, leaving 891,944 shares reported as directly beneficially owned after that transaction. On 09/09/2025 he sold 504 shares at a weighted average price of $17.5179, leaving 891,440 shares reported as directly beneficially owned after that transaction. The 10b5-1 plan was adopted on June 14, 2024 and has a stated end date of September 30, 2025. The filing also reports indirect holdings: 25,410 shares held by The John Franklin Watanabe Trust, 25,410 shares held by The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares held by Watanabe Ventures, LLC, and 124,956 shares held by The Watanabe 2016 Irrevocable Trust. The Form 4 was signed by an attorney-in-fact on 09/10/2025.
Arcutis Biotherapeutics, Inc. (ARQT) Form 144 reports a proposed sale of 504 common shares by a person for whose account the securities are to be sold, with an aggregate market value of $8,829 and an approximate sale date of 09/09/2025 on NASDAQ. The filing states these 504 shares were acquired on 05/01/2025 upon restricted stock vesting from Arcutis Biotherapeutics.
The filing also discloses prior sales by the same person in the past three months: 11,547 shares on 08/04/2025 for $165,429 and 9,625 shares on 09/08/2025 for $168,800. The filer certifies no undisclosed material adverse information and includes the standard attestation language required by Rule 144.
Masaru Matsuda, SVP General Counsel and Corporate Secretary of Arcutis Biotherapeutics, Inc. (ARQT), reported the sale of 36,130 shares of the issuer's common stock on 09/04/2025. The shares were sold in multiple transactions at prices ranging from $15.93 to $16.3787, with a reported weighted-average sale price of $16.156. Following these dispositions, Mr. Matsuda beneficially owns 161,234 shares. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2025 with a plan end date of September 4, 2026. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
Arcutis Biotherapeutics (ARQT) filed a Form 144 reporting proposed and recent insider sales. The filing names common stock with a proposed sale of 9,625 shares through Merrill (Columbus, OH) with an aggregate market value of $168,800 and an approximate sale date of 09/08/2025 on NASDAQ. The shares were acquired as restricted stock that vested on 05/01/2025, totaling 9,625 shares. The filing also discloses a sale on 08/04/2025 by Todd Franklin Watanabe of 11,547 common shares for gross proceeds of $165,429. The filer certifies no undisclosed material adverse information.
Arcutis Biotherapeutics director Howard G. Welgus executed planned transactions under a 10b5-1 trading plan on 09/02/2025. He exercised a fully vested stock option with a $1.6806 exercise price to acquire 10,000 shares and concurrently sold 10,000 common shares at a weighted average price of $15.6383, with sale prices ranging from $15.45 to $15.81. After these transactions he beneficially owned 100,206 shares. The 10b5-1 plan was adopted March 11, 2025, and runs through May 29, 2026.